A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

NCT02350673 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Atezolizumab
DRUG: Cergutuzumab Amunaleukin

Sponsor

Hoffmann-La Roche